Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.57−0.13 (-3.51%)
Close on Nov 18, 2026Market cap $99.44MP/E –Yield –
Unicycive Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Unicycive Therapeutics's total assets was $72.03M at Jun 30, 2026. For fiscal 2025 it was $49.14M, up 55.2% from the year before. The highest annual figure on record is $49.14M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.14M | +55.2% |
| FY2024 | Dec 31, 2024 | $31.67M | +123.2% |
| FY2023 | Dec 31, 2023 | $14.19M | +403.6% |
| FY2022 | Dec 31, 2022 | $2.82M | -85.0% |
| FY2021 | Dec 31, 2021 | $18.74M | +9088.2% |
| FY2020 | Dec 31, 2020 | $204.00K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.03M | +140.1% |
| Q1 FY2026 | Mar 31, 2026 | $64.41M | +130.5% |
| Q4 FY2025 | Dec 31, 2025 | $49.14M | +55.2% |
| Q3 FY2025 | Sep 30, 2025 | $50.61M | +31.2% |
| Q2 FY2025 | Jun 30, 2025 | $30.00M | -32.9% |
| Q1 FY2025 | Mar 31, 2025 | $27.95M | -46.7% |
| Q4 FY2024 | Dec 31, 2024 | $31.67M | +123.2% |
| Q3 FY2024 | Sep 30, 2024 | $38.57M | +98.4% |
| Q2 FY2024 | Jun 30, 2024 | $44.70M | +95.3% |
| Q1 FY2024 | Mar 31, 2024 | $52.39M | +92.6% |
| Q4 FY2023 | Dec 31, 2023 | $14.19M | +403.6% |
| Q3 FY2023 | Sep 30, 2023 | $19.44M | +91.0% |
| Q2 FY2023 | Jun 30, 2023 | $22.88M | +78.6% |
| Q1 FY2023 | Mar 31, 2023 | $27.20M | +72.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.82M | -85.0% |
| Q3 FY2022 | Sep 30, 2022 | $10.18M | -48.6% |
| Q2 FY2022 | Jun 30, 2022 | $12.82M | +1303.7% |
| Q1 FY2022 | Mar 31, 2022 | $15.76M | +7625.5% |
| Q4 FY2021 | Dec 31, 2021 | $18.74M | – |
| Q3 FY2021 | Sep 30, 2021 | $19.78M | – |
| Q2 FY2021 | Jun 30, 2021 | $913.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $204.00K | – |
See a number that looks wrong?